Role of tipranavir in treatment of patients with multidrug-resistant HIV

Abstract

The worldwide emergence of multidrug-resistant human immunodeficiency virus (HIV)-1 strains has the driven the development of new antiretroviral (ARV) agents. Over the past 5 years, HIV-entry and integrase inhibitor ARVs, as well as improved non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), have become available for treatment. It is important to assess how these new ARVs might be most judiciously used, paying close attention to viral susceptibility patterns, pharmacodynamic parameters, and the likelihood that patients will adhere to their therapy. Herein we review published material in Medline, EMBASE, and ISI for each antiretroviral agent/classes currently approved and summarize the available data on their efficacy, safety, and pharmacologic parameters. We focus on the role of tipranavir, a recently approved nonpeptidic PI, for treating HIV-infected children, adolescents, and adults with a history of multidrug-resistant HIV.

Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach

“…In addition, various viral protease inhibitors can inhibit proteases and reduce HIV and HCV to undetectable levels which employ aspartyl and serine proteases, respectively. Some of these drugs are now being repurposed for the treatment of COVID-19, which is also possesses a MPP [23] , [24] , [25] , [26] , [27] , [28] . A computational drug repurposing study has previously shown that many more drugs including Lopinavir and Ritonavir (also HIV-1 protease inhibitors) are capable of inhibiting SARS-CoV MPP and, therefore, could serve as a homologous target, as the previous SARS-CoV main protease has 96.1% similarity to SARS-CoV-2 MPP [29] , [30] .…”

Main Protease Inhibitors and Drug Surface Hotspot for the Treatment of COVID-19: Drug Repurposing and Molecular Docking Approach

“…Protease inhibitors are those drugs that can inhibit proteases and reduce levels of HIV and HCV to undetectable. Some of those drugs are now repurposing against the COVID-19, which is also a RNA virus and possesses the main protease [16][17][18][19]. Computational drug repurposing study previously showed Lopinavir and Ritonavir, two HIV-1 protease inhibitors were identified to be capable of inhibiting SARS-CoV main protease [20] that is why these the drugs used against HIV protease could be used as a homologous target as the previous SARS-CoV main protease has 96.1% of similarity with the SARS-CoV -2main protease [20].…”